Home
Live Updates
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors : comparemela.com
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2...
Related Keywords
United States ,
Haiyan ,
Yunnan ,
China ,
Italy ,
Sasayama ,
Hyogo ,
Japan ,
Canada ,
Spain ,
Zhejiang ,
Zaragoza ,
Baja California ,
Mexico ,
Switzerland ,
Toronto ,
Ontario ,
Sunnybrook ,
Alberta ,
Ivrea ,
Piemonte ,
American ,
America ,
Richard Jarvis ,
Satoshi Sugimoto ,
Marlena Abdinoor ,
Sloan Simpson ,
Michael Meo ,
Isabella Zinck ,
Imke Kappes ,
Simron Singh ,
Parag Mahanti ,
Julie Masow ,
Samir Shah ,
Jeff Legos ,
Jonathan Graham ,
Nicole Zinsli Somm ,
American Society Of Clinical Oncology ,
University Of Toronto ,
Sunnybrook Health Sciences Centre ,
Global Head Of Oncology Development At Novartis ,
Odette Cancer Centre ,
Linkedin ,
Exchange Commission ,
Instagram ,
Facebook ,
Novartis ,
Elsevier Inc ,
Clinical Oncology ,
Associate Professor ,
Susan Leslie Clinic ,
Neuroendocrine Tumours ,
Global Head ,
Oncology Development ,
Radioligand Therapy ,
Survival Outcomes ,
Patients With Neuroendocrine Tumors ,
Gastroenteropancreatic Neuroendocrine ,
Patients With Grade ,
Accessed January ,
Full Prescribing ,
Product Characteristics ,
Clinical Radiation ,
Markets ,
comparemela.com © 2020. All Rights Reserved.